MGB Biopharma Raises $1M in Financing

MGB Biopharma, a Glasgow, Scotland-based biopharmaceutical company developing a novel class of anti-infectives, has raised $1.15 million in financing. The round was led by Archangel Investors Ltd and included TRI Capital Ltd, Barwell plc and Scottish Investment Bank. The company will use the funds to advance its lead product, MGB-BP-3, towards a Phase II clinical trial.

MGB Biopharma Secures $1.15 Million to Advance Anti-Infective Drug

MGB Biopharma is a Glasgow, Scotland, UK-based biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance. The company's lead product, MGB-BP-3, is an antibacterial active against a broad range of important multi-resistant and susceptible Gram-positive pathogens. MGB Biopharma has developed an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile associated disease (CDAD) and is preparing for a Phase II study for this indication. An intravenous formulation targeting the treatment of a range of systemic hospital acquired Gram-positive infections is in late-stage preclinical development, and a topical formulation for the treatment of serious skin infections showed encouraging efficacy data.

MGB Biopharma develops a novel class of anti-infectives to address the major global problem of antibiotic resistance.

8 years ago

MGB Biopharma Secures $1.15 Million to Advance Anti-Infective Drug

ProblemHealthcare

Solution

Covered on